Mereo BioPharma is a clinical-stage biopharmaceutical company developing innovative medicines for serious rare diseases and other conditions with unmet medical needs. The company's pipeline includes lead rare-disease programs such as setrusumab (a monoclonal antibody for osteogenesis imperfecta developed in partnership with Ultragenyx), alvelestat (an inhaled serine protease inhibitor for alpha-1 antitrypsin deficiency), and vantictumab (licensed to partners for bone disease treatment), alongside out-licensed programs in reproductive medicine, oncology, and immuno-oncology. Mereo generates revenue through upfront payments and milestone fees from licensing partnerships, as well as tiered royalties on partner net sales, while retaining direct commercialization rights for selected rare-disease candidates in Europe and the U.K. and pursuing strategic partnerships for other indications.